TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Outcome Evaluations of a Daily Physical Activity Intervention for Individuals With Type 2 Diabetes
Brief Summary: The intervention consists of an individual counseling session, telephone counseling (7 calls), given by a psychologist, and a pedometer. The intervention is based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing. The taxonomy of behavior change techniques is also taken into account. The duration of the intervention is six months. The individual session takes place one week after the baseline measurements, together with the participants' follow-up appointment with their endocrinologist. The individual session takes place at the endocrinology department and is expected to last approximately 30 minutes. In addition to the session, the participants of the intervention group receive a pedometer and a pedometer diary for six months. Participants of the intervention group also receive telephone counseling from the psychologist during 24 weeks. They receive a call every two weeks for four weeks and then every four weeks for the next 20 weeks, good for a total of seven counseling calls. The calls are expected to last approximately 20 minutes. The Control Group has no intervention at all and receive their usual care.


Options:
A: Arm Label: access to intermediate care clinics; Type: EXPERIMENTAL; Interventions: Other: intermediate care clinics (ICCs) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intermediate care clinics (ICCs); Assigned to Arm(s): access to intermediate care clinics
B: Arm Label: Telemedicine case management; Type: EXPERIMENTAL; Interventions: Device: Telemedicine Unit (HTU) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: DEVICE; Name: Telemedicine Unit (HTU); Assigned to Arm(s): Telemedicine case management | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care
C: Intervention Type: BEHAVIORAL; Name: Telephonic diabetes care; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Daily physical activity, pedometer and counseling | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Daily physical activity, pedometer and counseling; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)- A Laboratory Classroom Study
Brief Summary: The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages 6-12 years with ADHD.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CONCERTA (methylphenidate HCl) / Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Placebo/ CONCERTA (methylphenidate HCl) | Intervention Type: DRUG; Name: Placebo/ CONCERTA (methylphenidate HCl); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CONCERTA (methylphenidate HCl) / Placebo; Assigned to Arm(s): 1
B: Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A
C: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
D: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Quillivant Oral Suspension XR, Drug: Placebo | Arm Label: Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Quillivant Oral Suspension XR; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Comparator

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)- A Laboratory Classroom Study
Brief Summary: The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages 6-12 years with ADHD.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Quillivant Oral Suspension XR, Drug: Placebo | Arm Label: Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Quillivant Oral Suspension XR; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Comparator
B: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System, Placebo patch
C: Arm Label: Aripirazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Quetiapine prolong; Type: EXPERIMENTAL; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripirazole | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine prolong
D: Arm Label: OROS Methylphenidate HCl; Type: EXPERIMENTAL; Interventions: Drug: OROS Methylphenidate HCl | Intervention Type: DRUG; Name: OROS Methylphenidate HCl; Assigned to Arm(s): OROS Methylphenidate HCl

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)- A Laboratory Classroom Study
Brief Summary: The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages 6-12 years with ADHD.


Options:
A: Arm Label: Methylphenidate Transdermal System (MTS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System (MTS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: NWP09 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NWP09; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylphenidate | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine, Drug: methylphenidate | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: clonidine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 4
D: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Quillivant Oral Suspension XR, Drug: Placebo | Arm Label: Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Quillivant Oral Suspension XR; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Comparator

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Interventions to Improve Warfarin Adherence
Brief Summary: The purpose of this research study is to see if a lottery which provides the opportunity to win money, a reminder system using a "Med-eMonitor", or the combination of both might be useful in helping patients to achieve better control of their anticoagulation therapy. Selection for the arms of the study is randomized by the study computer. Some will participate in the daily lottery only, some with the reminder system only, some with the reminder system and the daily lottery, and some with neither the lottery nor the reminder system.


Options:
A: Arm Label: 1 Usual Care Group/Control; Type: OTHER; Interventions: Behavioral: Financial Incentive and Med-eMonitor | Arm Label: 2Med-eMonitor/Reminder; Type: EXPERIMENTAL; Interventions: Device: 2Med-eMonitor | Arm Label: 3 Incentive Group/Lottery; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive and Med-eMonitor | Arm Label: 4 Combined Group/Lottery and Reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive and Med-eMonitor | Intervention Type: BEHAVIORAL; Name: Financial Incentive and Med-eMonitor; Assigned to Arm(s): 1 Usual Care Group/Control, 3 Incentive Group/Lottery, 4 Combined Group/Lottery and Reminder | Intervention Type: DEVICE; Name: 2Med-eMonitor; Assigned to Arm(s): 2Med-eMonitor/Reminder
B: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
C: Arm Label: CHESS + Case Mgt; Type: EXPERIMENTAL; Interventions: Behavioral: CHESS Internet telehealth | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHESS Internet telehealth; Assigned to Arm(s): CHESS + Case Mgt
D: Intervention Type: DRUG; Name: carvedilol plus nurse management; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pacific Kids DASH for Health
Brief Summary: The increasing prevalence of childhood overweight has been found to be related to decreased levels of physical activity (PA) and increased energy content of the diet. Childhood offers an opportunity to develop and support health-promoting behaviors. Pacific Kids DASH for Health (PacDASH) is a community-based intervention that links food, PA, and health, and targets overweight children in Hawaii with a goal of preventing further weight gain. Components of the intervention include a food and PA prescription delivered by physicians at community-based health centers complemented with a toolbox of activities, behaviorally tailored messages, and PacDASH educational materials. This project will extend and apply the nationally recommended DASH eating pattern to children and the growing population of Asians and Pacific Islanders. The investigators will incorporate culturally preferred foods, recipes, and PA messages that meet DASH and other national guidelines. The approach will target child food behaviors and social and environmental cues that are important to making healthy food and PA choices and will provide steps to behavior change. Farmers markets at participating health centers are a support resource for activities. Providing access to, coupons for, and guidance about selecting and preparing fresh fruits and vegetables at a convenient health center farmers market will support increased intake of nutrient-rich foods among these children who are overweight and at risk for obesity.

Pacific Islanders are among the world's most obese populations while Asians, although of relatively low body mass index (BMI), carry much of their body fat in the upper body and exhibit greater health risk at the same BMI. Through this project, the investigators hope to learn more about body size and composition in children of the Pacific Region for whom there are few national data. In addition, evaluate the effectiveness of a community-based intervention within a health care system on managing overweight in children.


Options:
A: Arm Label: Active video game play; Type: EXPERIMENTAL; Interventions: Behavioral: Active video game play | Intervention Type: BEHAVIORAL; Name: Active video game play; Assigned to Arm(s): Active video game play
B: Intervention Type: BEHAVIORAL; Name: To change structure and roles of primary care teams to optimize prevention of obesity; Assigned to Arm(s): N/A
C: Arm Label: "Fortaleça sua Saúde" program; Type: EXPERIMENTAL; Interventions: Behavioral: "Fortaleça sua Saúde" program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: "Fortaleça sua Saúde" program; Assigned to Arm(s): "Fortaleça sua Saúde" program
D: Arm Label: Attention Control / Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PacDASH intervention | Intervention Type: BEHAVIORAL; Name: PacDASH intervention; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Warm Water Irrigation Versus Standard Air Insufflation for Unsedated Colonoscopy: a Randomized Controlled Trial
Brief Summary: Unsedated colonoscopy is characterized by lower costs, recovery time and incidence of drug-related side effects, although it may be painful for the patient. Based on recent reports, the investigators designed this randomized controlled trial hypothesizing that the use of water irrigation versus air insufflation during the insertion phase of colonoscopy might increase the global tolerability of the examination and the proportion of patients undergoing complete colonoscopy without sedation.


Options:
A: Arm Label: CO2; Type: EXPERIMENTAL; Interventions: Procedure: CO2 | Arm Label: Warm Water irrigation; Type: EXPERIMENTAL; Interventions: Procedure: Warm water | Intervention Type: PROCEDURE; Name: CO2; Assigned to Arm(s): CO2 | Intervention Type: PROCEDURE; Name: Warm water; Assigned to Arm(s): Warm Water irrigation
B: Arm Label: warm water; Type: EXPERIMENTAL; Interventions: Procedure: warm water irrigation | Arm Label: air; Type: ACTIVE_COMPARATOR; Interventions: Procedure: air insufflation | Intervention Type: PROCEDURE; Name: warm water irrigation; Assigned to Arm(s): warm water | Intervention Type: PROCEDURE; Name: air insufflation; Assigned to Arm(s): air
C: Arm Label: Water infusion; Type: EXPERIMENTAL; Interventions: Procedure: Water infusion | Arm Label: Air insufflation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Air insufflation | Intervention Type: PROCEDURE; Name: Water infusion; Assigned to Arm(s): Water infusion | Intervention Type: PROCEDURE; Name: Air insufflation; Assigned to Arm(s): Air insufflation
D: Intervention Type: PROCEDURE; Name: water infusion colonoscopy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Perioperative Administration of Pregabalin for Pain After Robot-assisted Endoscopic Thyroidectomy
Brief Summary: The investigators hypothesize that pregabalin will decrease post-operative pain scores and analgesic use following robot-assisted endoscopic thyroidectomy compared to placebo. The primary outcome will be acute postoperative pain, measured by a verbal numerical rating score (VNRS) and total analgesic consumption during postoperative 48 hours. The secondary outcome will be the incidence of chronic pain and hypoesthesia in the anterior chest at 3 months after operation.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin Complex (placebo) | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Vitamin Complex (placebo); Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Intervention Type: PROCEDURE; Name: perioperative epidural catheter; Assigned to Arm(s): 1, 2, 3, 4, 5
C: Arm Label: Gabapentin preoperatively; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Active placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diphenhydramine | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin preoperatively | Intervention Type: DRUG; Name: Diphenhydramine; Assigned to Arm(s): Active placebo
D: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months.
Brief Summary: The clinical investigation is a prospective, international, multi-centre, randomized (1:1) trial with follow up investigations at 1, 3, 6 and 12 months. Patients will be randomized either to treatment with stenting with the Astron Pulsar SE (4 or 5 mm diameter) stent or to PTA with optional bailout stenting in case of PTA failure.

The primary objective of this study is to show clinical improvement in the outcome of patients with symptomatic critical limb ischemia or severe intermittent claudication (Rutherford 3, 4, 5) treated with the Astron Pulsar SE (4 or 5 mm diameter) in comparison with PTA or optional bailout stenting in case of PTA failure.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: XIENCE V everolimus eluting coronary stent system | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: MULTILINK VISION coronary stent system | Intervention Type: DEVICE; Name: XIENCE V everolimus eluting coronary stent system; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: MULTILINK VISION coronary stent system; Assigned to Arm(s): 2
B: Arm Label: Drug Coated Balloon (DCB) Arm; Type: EXPERIMENTAL; Interventions: Procedure: Paclitaxel coated balloon angioplasty. | Arm Label: Drug Eluting Stents (DES) Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infrapopliteal Primary Drug Eluting Stenting | Intervention Type: PROCEDURE; Name: Paclitaxel coated balloon angioplasty.; Assigned to Arm(s): Drug Coated Balloon (DCB) Arm | Intervention Type: PROCEDURE; Name: Infrapopliteal Primary Drug Eluting Stenting; Assigned to Arm(s): Drug Eluting Stents (DES) Arm
C: Arm Label: Astron Pulsar Stent; Type: EXPERIMENTAL; Interventions: Device: Astron Pulsar Stent | Arm Label: PTA alone; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA alone | Intervention Type: DEVICE; Name: Astron Pulsar Stent; Assigned to Arm(s): Astron Pulsar Stent | Intervention Type: DEVICE; Name: PTA alone; Assigned to Arm(s): PTA alone
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Implantation of YUKON Sirolimus-eluting Stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Implantation of YUKON Stent (uncoated) | Intervention Type: DEVICE; Name: Implantation of YUKON Sirolimus-eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Implantation of YUKON Stent (uncoated); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Trial to Assess Safety of Single Dose vs. Traditional Administration of Thymoglobulin Induction for Renal Transplantation
Brief Summary: In a non-blinded pilot study conducted at the University of Nebraska Medical Center, evidence was found that a single large dose of Thymoglobulin on the day of kidney transplantation produced better kidney function than the standard dosing plan, when the same amount is divided into smaller doses on 4 days. This new study repeats that dose comparison, but with double-blinding and at multiple transplantation centers.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: mycophenolate mofetil, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: mycophenolate mofetil, Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - single dose; Assigned to Arm(s): Group 1, Group 3 | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - 4 doses; Assigned to Arm(s): Group 2, Group 4 | Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4 | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus/Sirolimus | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus/MMF | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Neoral/Sirolimus | Intervention Type: DRUG; Name: Tacrolimus/Sirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Tacrolimus/MMF; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Neoral/Sirolimus; Assigned to Arm(s): C
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Single-dose Thymoglobulin; Type: EXPERIMENTAL; Interventions: Biological: Single-dose rabbit Anti-thymocyte Globulin induction | Arm Label: Divided-dose Thymoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Biological: Divided-dose rabbit Anti-thymocyte Globulin induction | Intervention Type: BIOLOGICAL; Name: Single-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Single-dose Thymoglobulin | Intervention Type: BIOLOGICAL; Name: Divided-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Divided-dose Thymoglobulin

Answer: D